Literature DB >> 2455472

Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters.

J Jankovic1, T C Caskey, J T Stout, I J Butler.   

Abstract

We studied 5 boys, 2 to 10 years old, with marked or complete deficiency of hypoxanthine-guanine phosphoribosyltransferase and Lesch-Nyhan syndrome with varying degrees of mental retardation, dysarthria, chorea, dystonia, spasticity, and ataxia. Four patients had marked reduction of homovanillic acid in the cerebrospinal fluid (CSF) and all showed low CSF 3-methoxy-4-hydroxy phenylethylene glycol, indicating reduced dopamine and norepinephrine turnover. Three patients showed high CSF 5-hydroxyindoleacetic acid, suggesting increased serotonin turnover. Some patients improved with carbidopa-levodopa, but others benefited from tetrabenazine, a monoamine-depleting agent. This study provides support for the theory of abnormal central monoamine metabolism in Lesch-Nyhan syndrome.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455472     DOI: 10.1002/ana.410230507

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

1.  Adenosine, dopamine and serotonin receptors imbalance in lymphocytes of Lesch-Nyhan patients.

Authors:  Marta G García; Juan G Puig; Rosa J Torres
Journal:  J Inherit Metab Dis       Date:  2012-03-09       Impact factor: 4.982

2.  Regional brain volume abnormalities in Lesch-Nyhan disease and its variants: a cross-sectional study.

Authors:  David J Schretlen; Mark Varvaris; Tiffany E Ho; Tracy D Vannorsdall; Barry Gordon; James C Harris; H A Jinnah
Journal:  Lancet Neurol       Date:  2013-12       Impact factor: 44.182

Review 3.  Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach.

Authors:  Noha F Minshawi; Sarah Hurwitz; Danielle Morriss; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2015-06

Review 4.  Lesch-Nyhan Syndrome: Models, Theories, and Therapies.

Authors:  Scott Bell; Ilaria Kolobova; Liam Crapper; Carl Ernst
Journal:  Mol Syndromol       Date:  2016-09-24

5.  Elevated UTP and CTP content in cultured neurons from HPRT-deficient transgenic mice.

Authors:  S Brosh; P Boer; O Sperling; E Zoref-Shani
Journal:  J Mol Neurosci       Date:  2000 Feb-Apr       Impact factor: 3.444

6.  Analysis of abnormalities in purine metabolism leading to gout and to neurological dysfunctions in man.

Authors:  R Curto; E O Voit; M Cascante
Journal:  Biochem J       Date:  1998-02-01       Impact factor: 3.857

7.  Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo.

Authors:  D F Wong; J C Harris; S Naidu; F Yokoi; S Marenco; R F Dannals; H T Ravert; M Yaster; A Evans; O Rousset; R N Bryan; A Gjedde; M J Kuhar; G R Breese
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

Review 8.  Mouse models of hypoxanthine phosphoribosyltransferase deficiency.

Authors:  D J Williamson; M L Hooper; D W Melton
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

Review 9.  Delineation of the motor disorder of Lesch-Nyhan disease.

Authors:  H A Jinnah; Jasper E Visser; James C Harris; Alfonso Verdu; Laura Larovere; Irene Ceballos-Picot; Pedro Gonzalez-Alegre; Vladimir Neychev; Rosa J Torres; Olivier Dulac; Isabelle Desguerre; David J Schretlen; Kenneth L Robey; Gabor Barabas; Bastiaan R Bloem; William Nyhan; Raquel De Kremer; Gary E Eddey; Juan G Puig; Stephen G Reich
Journal:  Brain       Date:  2006-03-20       Impact factor: 13.501

10.  Hypoxanthine-guanine phosphoribosyl transferase regulates early developmental programming of dopamine neurons: implications for Lesch-Nyhan disease pathogenesis.

Authors:  Irene Ceballos-Picot; Lionel Mockel; Marie-Claude Potier; Luce Dauphinot; Thomas L Shirley; Raoul Torero-Ibad; Julia Fuchs; H A Jinnah
Journal:  Hum Mol Genet       Date:  2009-04-02       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.